JPMorgan raised the firm’s price target on Elevance Health (ELV) to $394 from $384 and keeps an Overweight rating on the shares. The firm updated the company’s model post the earnings report.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELV:
- Elevance Health price target raised to $380 from $330 at TD Cowen
- Elevance Health: Strategic Outlook and EPS Growth Support Buy Rating
- Elevance Health price target lowered to $385 from $395 at Barclays
- Elevance Health Reports Strong Q3 2025 Revenue Growth
- Morning Movers: General Motors and RTX higher following Q3 reports